Quick Facts
  • wavy circle icon with check mark inside
    Clinical Trials
  • magnifying glass with heart icon
  • gender symbols interlocked icon
  • chat box with different language translations icon
  • pin location icon
    Primary Location:
    Hillman Cancer Center

Get to Know Dr. Antoinette Wozniak

Dr. Antoinette Wozniak has been a medical oncologist for more than 30 years, specializing in the treatment of lung cancer, malignant mesothelioma and thymus gland cancer.

She also is the associate director of clinical research for the Hillman Cancer Center at the University of Pittsburgh. Board certified in internal medicine, hematology and medical oncology, Wozniak spent 25 years at the Karmanos Cancer Institute in Detroit before coming to Pittsburgh.

At Karmanos she did extensive research, including one study involving the plasma biomarker enrichment of clinical prognostic indices in pleural mesothelioma. Her co-authors of that study were Dr. Anne Tsao of MD Anderson Cancer Center and Dr. Michele Carbone from the University of Hawaii Cancer Center, both well-known specialists in mesothelioma.

Wozniak was an early pioneer with cancer immunotherapy, having success treating lung cancer patients with the combination of pembrolizumab and platinum-based chemotherapy. That combination recently has been adopted by oncologists treating mesothelioma.

She is part of a personalized, multidisciplinary program at the Hillman Cancer Center that includes surgeons, radiologists and pulmonologists.

Specialties of Dr. Antoinette Wozniak 

Dr. Antoinette Wozniak’s Experience and Education

  • UPMC Hillman Cancer Center
  • Karmanos Cancer Institute, Wayne State University School of Medicine
  • University of Florida, Department of Medicine (Fellowship)
  • State University of New York at Buffalo Affiliated Hospitals (Residency)
  • State University of New York at Buffalo School of Medicine (M.D.)

Awards and Certifications

  • Outstanding Teaching Award, Division of Hematology/Oncology, Wayne State University (2016)
  • Frank Ellis Medal, The Royal College of Radiologists (2016)
  • Top Docs, Hour Detroit Magazine (2012-2014, 2016)
  • Board certified in internal medicine, hematology and medical oncology
  • American Association of Cancer Research (Member)
  • American Society of Clinical Oncology (Member)

Mesothelioma Clinical Trials Under Dr. Antoinette Wozniak

  • A phase II clinical trial studying the effectiveness of nintedanib, also called Ofev, in treating patients with recurrent pleural mesothelioma. Earlier findings have shown it may stop tumor growth by negating particular enzymes.

Publications of Dr. Antoinette Wozniak

  • Nagasaka, M. et al. (2019, September). A retrospective study evaluating the pretreatment tumor volume (PTV) in non-small cell lung cancer (NSCLC) as a predictor of response to program death-1 (PD-1) inhibitors. Lung Cancer.
  • Gadgeel, S.M. et al. (2018, May). Phase II Study of Maintenance Pembrolizumab in Patients with Extensive-Stage Small Cell Lung Cancer (SCLC). Journal of Thoracic Oncology.
  • Thakur, M.K. et al. (2017, October). Risk of Second Lung Cancer in Patients With Previously Treated Lung Cancer: Analysis of Surveillance, Epidemiology, and End Results (SEER) Data. Journal of Thoracic Oncology.
  • Pass, H.I. et al. (2016, February). Plasma Biomarker Enrichment of Clinical Prognostic Indices in Malignant Pleural Mesothelioma.  Journal of Thoracic Oncology.